Experimental and clinical studies of drug treatment for liver fibrosis development of carbon-tetrachloride-induced cirrhosis in rats. Gut, 2004, 53(7): 1010-1020. Shimizu I. Antifibrogenic therapies in chronic HCV infection. Current Drug Targets Infectious Disorders, 2001, 1: 227-236. Oaldey F, Trim N, Constantinou CM. Hepatocytes express nerve growth factor during liver injury: evidence for paracrine regulation of hepatic stellate cell apoptosis. American Journal of Pathology, 2003, 163(5): 1849-1860. Orr JG, Leel V, Cameron GA, et al. Mechanism of action of the antifibrogenic compound gliotoxin in rat liver cells. Hepatology, 2004, 40(1): 232-240. Jing Thread Bin, John Reading, Lu Hanming. Verapamil on rat liver fat-storing cell proliferation. Gastroenterology and Hepatology, 1998, 7(3): 253-258. Gringreiff K, Reinhold D. Liver cirrhosis and MedIterypotheses, 2005, 64(2): 316-322. Research profile of pumpkin polysaccharide on diabetic hypoglycemic effect by Tang Jun (Tianjin First Central Hospital, Tianjin 300192). Abstract This paper reviews the screening and identification of pumpkin polysaccharide, separation and purification, physical and chemical nature, composition quantitative analysis, its hypoglycemic effect in alloxan-diabetic rats, and diabetic effects. Pumpkin polysaccharide has no toxic side effects and will serve as an efficient and low toxicity drug entering the ranks of oral hypoglycemic agents, with a promising outlook. Keywords: pumpkin polysaccharide, diabetes, lowering blood sugar, separation and purification, physical and chemical properties. In the past 10 years, it was discovered that a polysaccharide extracted from plants has a wide range of biological functions, including lowering blood sugar, lowering blood pressure, cancer, and other reactive functions. Received Date: 2005-07-15.